Renal Biomarkers Market

Global Renal Biomarkers Market:

The global renal biomarkers market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The increasing public health concerns and its main risk factors, including hypertension, diabetes, and heart diseases, are bolstering the market.

Renal Biomarkers Market Analysis:

• Major Market Drivers: The rising need for diagnosis of chronic kidney disease (CKD) and monitoring of the disease is one of the key factors bolstering the market. Additionally, the expanding healthcare industry is also acting as another significant growth-inducing factor.
• Key Market Trends: The increasing inclination among industry investors towards novel single biomarkers and process-specific biomarker panels in human renal diseases is stimulating the overall market.
• Competitive Landscape: Some of the prominent companies in the global market include Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG, and Thermo Fisher Scientific Inc., among many others.
• Geographical Trends: North America exhibits a clear dominance in the market, owing to the increasing geriatric population. Additionally, the growing number of clinical trials for CKD will continue to fuel the regional market over the forecasted period.
• Challenges and Opportunities: One of the primary challenges hindering the market is the lack of standardization and validation across different biomarkers. However, the introduction of uniform protocols to ensure reliability and accuracy is expected to catalyze the market in the coming years.
   

Renal Biomarkers Market Trends:

Growing Advancements in Diagnostic Technologies

Continuous technological advancements for enhancing the precision and speed of kidney disease detection are stimulating the market. For instance, in March 2024, AI-powered pathology solutions provider Aiosyn launched its NephroPath platform to provide a detailed evaluation of histological renal biomarkers in kidney biopsies, enhancing the speed of drug development studies. Moreover, Abbott's ARCHITECT c4000, which uses advanced immunoassay techniques to measure renal biomarkers, exemplifies this trend. This is escalating the renal biomarkers market demand

Rising Prevalence of Chronic Kidney Disease

The increasing occurrence of CKD is acting as a significant growth-inducing factor. The escalating demand for early detection and monitoring tools is bolstering the market. For example, in May 2024, Bio-Techne Corporation and Regulus Therapeutics Inc. announced continued technical and clinical collaboration following the release of Regulus' positive topline results from the second cohort of patients. Apart from this, Siemens Healthineers' DCA Vantage Analyzer, which provides rapid and accurate testing for kidney function biomarkers, is positively influencing the renal biomarkers market outlook.

Expansion of Clinical Research

There is an emerging trend of expanding clinical research on renal biomarkers, driven by the rising need for better diagnostic and therapeutic solutions. Additionally, numerous clinical trials are underway to validate new biomarkers and their effectiveness, which is elevating the renal biomarkers market statistics. For instance, in March 2024, Panoramic Health, kidney care's leading integrated provider group, established its Scientific Advisory Board, a distinguished group of research experts and clinical leaders committed to advancing kidney care innovation. Apart from this, bioMérieux's NephroCheck test, which assesses the risk of acute kidney injury, has undergone extensive clinical validation, showcasing the market's focus on evidence-based products. This, in turn, is elevating the renal biomarkers market's recent price.

Global Renal Biomarkers Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the renal biomarkers market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on the biomarker type, diagnostic technique, and end user.

Breakup by Biomarker Type:

• Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
• Up-regulated Protein
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Kidney Injury Molecule-1
  • INTERLEUKIN-18
• Others
   

Functional biomarker currently exhibits a clear dominance in the market

The report has provided a detailed breakup and analysis of the market based on the biomarker type. This includes functional biomarker(serum creatinine, serum cystatin C, and urine albumin), up-regulated protein (neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1, interleukin-18), and others. According to the report, functional biomarker represented the largest market segmentation.

Functional biomarkers are measurable indicators that provide critical insights into physiological processes and disease states, enabling precise diagnosis and monitoring of therapeutic responses. Unlike traditional biomarkers, which indicate the mere presence of a disease, functional biomarkers reveal the functional status and activity of biological systems. A notable example is the recent launch of Thermo Fisher Scientific's procalcitonin assay, a functional biomarker used to assess bacterial infections and guide antibiotic therapy. This represents one of the renal biomarkers market recent opportunities.

Breakup by Diagnostic Technique:

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)
   

Currently, enzyme-linked immunosorbent assay (ELISA) holds the largest renal biomarkers market share

The report has provided a detailed breakup and analysis of the market based on the diagnostic technique. This includes enzyme-linked immunosorbent assay (ELISA), particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography mass spectrometry (LC-MS). According to the report, enzyme-linked immunosorbent assay (ELISA) represented the largest market segmentation.

The enzyme-linked immunosorbent assay (ELISA) is a widely used laboratory technique for detecting and quantifying antigens or antibodies in a sample, leveraging the specificity of antibodies and the sensitivity of enzyme detection. This method is essential in diagnostics, research, and quality control. A notable recent product launch is Bio-Rad Laboratories' S3e ELISA System, designed to streamline the ELISA workflow with enhanced automation and precision. This system features a user-friendly interface, high-throughput capabilities, and integrated data analysis software, making it a valuable tool for researchers and clinicians. The S3e ELISA System exemplifies advancements in ELISA technology, offering improved efficiency and accuracy in various applications, from disease diagnostics to biomarker discovery.

Breakup by End User:

• Hospital
• Diagnostic Laboratory
• Others
   

Diagnostic laboratory account for the majority of the total renal biomarkers market revenue

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospital, diagnostic laboratory, and others. According to the report, diagnostic laboratory represented the largest market segmentation.

Diagnostic laboratories represent the largest segmentation in the market due to their pivotal role in the early detection, diagnosis, and monitoring of kidney diseases. These laboratories are equipped with advanced technologies and skilled personnel capable of performing complex tests that measure specific renal biomarkers, such as serum creatinine, cystatin C, and neutrophil gelatinase-associated lipocalin (NGAL). The demand for accurate and timely diagnostic services is driven by the increasing prevalence of chronic kidney disease (CKD) and acute kidney injury (AKI) globally.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America currently dominates the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share. 

As per the renal biomarkers market overview, the region is characterized by significant growth due to the high prevalence of kidney diseases, advanced healthcare infrastructure, and strong focus on research and development. In the United States and Canada, there is an increasing demand for early diagnostic and monitoring tools to manage chronic kidney disease (CKD) and acute kidney injury (AKI). Prominent examples include the widespread use of BioPorto's NGAL Test, which aids in the early detection of AKI, and Abbott's ARCHITECT i2000SR system, which measures cystatin C levels to assess kidney function. The region's robust investment in healthcare technology and the presence of leading diagnostic companies drive innovation and adoption of new biomarker tests, ensuring better patient outcomes and enhancing the market's growth.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major renal biomarkers market companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Beckman Coulter Inc. (Danaher Corporation)
• bioMérieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc.
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Renal Biomarkers Market Recent Developments:

• May 2024: Bio-Techne Corporation and Regulus Therapeutics Inc. announced continued technical and clinical collaboration following the release of Regulus' positive topline results from the second cohort of patients.
• March 2024: Panoramic Health, kidney care's leading integrated provider group, established its Scientific Advisory Board, a distinguished group of research experts and clinical leaders committed to advancing kidney care innovation.
• March 2024: AI-powered pathology solutions provider Aiosyn launched its NephroPath platform to provide a detailed evaluation of histological renal biomarkers in kidney biopsies, enhancing the speed of drug development studies.

Renal Biomarkers Market Report Scope:

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the renal biomarkers market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global renal biomarkers market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the renal biomarkers industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.